A phase Ib study of pre-operative, locoregional IRX-2 cytokine immunotherapy to prime immune responses in patients with early stage breast cancer.

CONCLUSIONS: IRX-2 is safe in early stage breast cancer. Potentially favorable immunomodulatory changes were observed, supporting further study of IRX-2 in early stage breast cancer and other malignancies.
PMID: 31831558 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 11, 2019 Category: Cancer & Oncology Authors: Page DB, Pucilowska J, Sanchez KG, Conlin AK, Acheson AK, Perlewitz KS, Imatani JH, Aliabadi-Wahle S, Moxon N, Mellinger SL, Seino AY, Martel M, Wu Y, Sun Z, Redmond WL, Conrad VK, Rajamanickam V, Waddell D, Laxague D, Shah M, Chang SC, Urba WJ Tags: Clin Cancer Res Source Type: research